Stockscreener 앱 받기
1.52
7.32%
-0.12
시장 영업 전:
1.61
0.09
+5.92%
Entera Bio Ltd 주식(ENTX)의 최신 뉴스
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 - GlobeNewswire Inc.
ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead - Asianet Newsable
Insider Buying: Steven Rubin Acquires Shares of Entera Bio Ltd (ENTX) - GuruFocus
Sean Ellis Buys 18,000 Shares of Entera Bio (NASDAQ:ENTX) Stock - MarketBeat
Insider Buying: Entera Bio (NASDAQ:ENTX) Director Buys 10,000 Shares of Stock - MarketBeat
Entera Bio Shares Rise After Open Market Purchase By Board Members - Nasdaq
Entera Bio Ltd. Board Members and CEO Purchase Company Shares Amid Ongoing Development of Oral Therapies - Quiver Quantitative
Entera Bio insiders are buying more of their own shares on market - Stock Titan
Entera Bio appoints Geno Germano as board chairman By Investing.com - Investing.com South Africa
Entera Bio appoints former Pfizer executive Geno J. Germano as chairman of the board ahead of key milestones - marketscreener.com
Entera Bio Ltd: Geno J. Germano appointed as chairman of Entera Bio - marketscreener.com
Entera Bio Ltd. Announces Board Changes - marketscreener.com
Entera Bio Attracts Former Pfizer Group President as It Enters a New Phase (NASDAQ: ENTX) - GuruFocus
Entera Bio appoints Geno Germano as board chairman - Investing.com
Entera Bio Names Geno Germano Independent Board Chairman - The Globe and Mail
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones - The Manila Times
Entera Bio Ltd. Appoints Geno J. Germano as New Chairman of the Board as Company Advances Oral Peptide Pipeline - Quiver Quantitative
Ex-Pfizer exec to lead Entera Bio board as 2026 oral PTH trials planned - Stock Titan
Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Geno J. Germano - Longbridge
Aug Fed Impact: Can Entera Bio Ltd deliver consistent dividendsMarket Trend Review & Community Driven Trade Alerts - baoquankhu1.vn
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development - Finviz
Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Steven D. Rubin - Longbridge
OPKO and Entera expand collaboration to develop oral PTH treatment By Investing.com - Investing.com Nigeria
Stop Loss: Should I invest in Entera Bio Ltd before earningsJuly 2025 Rallies & Reliable Trade Execution Plans - baoquankhu1.vn
OPKO and Entera expand collaboration to develop oral PTH treatment - Investing.com
Entera Bio Expands OPKO Partnership, Adds New Director - TipRanks
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism - The Manila Times
OPKO Health and Entera Bio expand partnership for oral PTH tablet - StreetInsider
Entera Bio Signs Amended And Restated Collaboration And License Agreement With OPKO - TradingView
Entera Bio Ltd. Announces Board Changes, Effective February 1, 2026 - marketscreener.com
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board - Stock Titan
OPKO Health and Entera Bio Expand Partnership to Advance - GlobeNewswire
Breakout Move: Can Entera Bio Ltd weather a recessionJuly 2025 Earnings & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth? - simplywall.st
Contrasting Entera Bio (NASDAQ:ENTX) and Barinthus Biotherapeutics (NASDAQ:BRNS) - Defense World
Is Entera Bio Ltd. on track to beat earnings2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - mfd.ru
Entera Bio Prepares For Key Q1 Milestones As EB613 Nears Phase 3 Transition - RTTNews
Investment Review: Can Launch One Acquisition Corp Debt Equity Composite Units weather a recessionGap Down & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Entera Bio plans FDA submission for osteoporosis drug in Q1 2026 - Investing.com Nigeria
Entera Bio Ltd. Announces Key Milestones and Upcoming FDA Submissions for EB613 and Oral Hypoparathyroidism Programs in Q1 2026 - Quiver Quantitative
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook - Sahm
Entera Bio (NASDAQ:ENTX) Trading Down 3.1%Here's Why - MarketBeat
Aug Levels: Is Entera Bio Ltd still a buy after recent gainsPortfolio Gains Summary & Risk Controlled Daily Plans - baoquankhu1.vn
What margin trends mean for Entera Bio Ltd. stock2025 Fundamental Recap & Community Verified Trade Alerts - Улправда
Will Entera Bio Ltd. stock remain a Wall Street favoriteJuly 2025 Momentum & Technical Confirmation Alerts - Улправда
Is Entera Bio Ltd. stock oversold or undervalued2025 Buyback Activity & Reliable Price Action Trade Plans - Улправда
Is Entera Bio Ltd. (5DT) stock prepared for digital transitionRate Hike & Long-Term Capital Growth Ideas - Улправда
Entera Bio Ltd.Ordinary Shares (NQ: ENTX - FinancialContent
Breakout Watch: Can Entera Bio Ltd 5DT stock surprise with quarterly results2025 Technical Overview & Low Drawdown Momentum Ideas - moha.gov.vn
[Form 4] Entera Bio Ltd. Insider Trading Activity - Stock Titan
Entera Bio Ltd. (NASDAQ: ENTX) director reports 2026 share and option grants - Stock Titan
Entera Bio (ENTX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation - Yahoo Finance
Entera Bio (NASDAQ:ENTX) CEO Miranda Jayne Toledano Acquires 11,000 Shares - MarketBeat
Entera Bio Ltd. Stock (ENTX) Opinions on Insider Buying and Clinical Updates - Quiver Quantitative
ENTX Insider Trading - Quiver Quantitative
Aug Retail: What margin trends mean for Entera Bio Ltd stockPortfolio Performance Report & Daily Risk Controlled Trade Plans - moha.gov.vn
1.24%
0.19%
자본화:
|
볼륨(24시간):